Phio PharmaceuticalsNASDAQ: PHIO

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock. About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells.

Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-9. The reverse stock split will become effective at 12:01 a.m.

Phio to present a clinical study progress update on their lead clinical candidate, PH-762 Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its lead product candidate, PH-762, an INTASYL compound, at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago, Illinois. Phio is reporting on the completion of the first dose cohort for its on-going open-label Phase 1b clinical study (NCT 06014086) which is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma.

Phio Pharmaceuticals Corp., a biotechnology company focused on improving immune cell effectiveness in killing tumor cells through its INTASYL™ siRNA gene silencing technology, has signed a purchase agreement with TRITON Funds.

Phio Pharma (NASDAQ: PHIO ) stock is pulling back on Thursday after the immuno-oncology therapeutics company's shares underwent a major rally yesterday. Investors will note that the company's stock saw a 91.2% price increase during normal trading hours on Wednesday.

Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.